GP
ALNY icon

GLG Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

GLG Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$152K Buy
+1,200
New +$151K 0.01% 393
2016
Q1 		– Sell
-50,342
Closed -$4.74M – 407
2015
Q4 		$4.74M Sell
50,342
-6,939
-12% -$643K 0.15% 164
2015
Q3 		$4.6M Buy
+57,281
New +$6.36M 0.12% 185

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BRC
Blue Ridge Capital New York $215M AUM

GLG Partners's ALNY Position: Q4 2017 in Review

GLG Partners opened a new position in Alnylam Pharmaceuticals (ALNY) in Q4 2017: 1,200 shares worth $152K. The stake represents 0.01% of the portfolio and ranks #393 among its holdings. This is a return to the name: GLG Partners previously reported a position in ALNY as recently as Q4 2015.

GLG Partners first reported a position in ALNY in Q3 2015 and has held it in 3 quarters since. The position peaked at $4.74M in Q4 2015. 282 funds tracked by Wall St. Rank hold ALNY as of Q4 2017.

  • GLG Partners held 1,200 shares of Alnylam Pharmaceuticals worth $152K as of Q4 2017.
  • Alnylam Pharmaceuticals was a new GLG Partners position in Q4 2017.
  • Alnylam Pharmaceuticals made up 0.01% of GLG Partners's portfolio in Q4 2017, its #393 holding.
  • GLG Partners first reported a position in Alnylam Pharmaceuticals in Q3 2015 and has held it in 3 quarters since.
  • GLG Partners's Alnylam Pharmaceuticals position peaked at $4.74M in Q4 2015.
  • 282 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2017.

Based on GLG Partners's 13F filing for Q4 2017, filed 14 Feb 2018.